Review Article

Management of Acute Stroke

Authors: Richard M. Zweifler, MD

Abstract

Stroke ranks as the third leading cause of death and the most common cause of permanent disability in adults. Timely recognition and treatment is imperative to reduce stroke-related morbidity and mortality. Patients with acute ischemic stroke should be evaluated for administration of intravenous tissue plasminogen activator (t-PA); those who do not qualify for t-PA should receive aspirin therapy in the absence of a contraindication. In all stroke patients, intravenous hydration with normal saline should be administered, hypoxia should be corrected with supplemental oxygen, and hyperglycemia and fever should be treated aggressively. Blood pressure management should be individualized on the basis of stroke pathophysiology and specific treatment plan (e.g., planned thrombolysis) following published guidelines. Evaluation of stroke etiology should be undertaken, and the results should be used to guide secondary stroke prevention efforts.

This content is limited to qualifying members.

Existing members, please login first

If you have an existing account please login now to access this article or view purchase options.

Purchase only this article ($25)

Create a free account, then purchase this article to download or access it online for 24 hours.

Purchase an SMJ online subscription ($75)

Create a free account, then purchase a subscription to get complete access to all articles for a full year.

Purchase a membership plan (fees vary)

Premium members can access all articles plus recieve many more benefits. View all membership plans and benefit packages.

References

  1. 1. Broderick J, Brott T, Kothari R, Miller R, Khoury J, Pancioli A, et al. The Greater Cincinnati/Northern Kentucky Stroke Study: Preliminary first-ever and total incidence rates of stroke among blacks. Stroke 1998; 29: 415–421.
  2. 2. Black-Schaffer RM, Osberg JS. Return to work after stroke: Development of a predictive model. Arch Phys Med Rehabil 2002; 71: 285–290.B
  3. 3. American Heart Association. Targeting the Facts. Dallas, American Heart Association, 2002(pamphlet).
  4. 4. Schwarz S, Georgiadis D, Aschoff A, Schwab S. Effects of body position on intracranial pressure and cerebral perfusion in patients with large hemispheric stroke. Stroke 2002; 33: 497–501.
  5. 5. Broderick JP, Adams HP Jr, Barsan W, Feinberg W, Feldmann E, Grotta J, et al. Guidelines for the management of spontaneous intracerebral hemorrhage: A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Stroke 1999; 30: 905–915.
  6. 6. Cummins RO (ed). Acute stroke, in Textbook of Advanced Cardiac Life Support. Dallas, American Heart Association, 1997, pp 10-1–10-28.
  7. 7. Quality Standards Subcommittee, American Academy of Neurology. Practice advisory: Thrombolytic therapy for acute ischemic stroke: Summary statement. Report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 1996; 47: 835–839.
  8. 8. Adams HP, Brott TG, Furlan AJ, Gomez CR, Grotta J, Helgason CM, et al. Guidelines for thrombolytic therapy for acute stroke: A supplement to the guidelines for the management of patients with acute ischemic stroke—A statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association. Circulation 1996; 94: 1167–1174.
  9. 9. Chen Z, Sandercock P, Pan H, Counsell C, Collins R, Liu L, et al. Indications for early aspirin use in acute ischemic stroke: A combined analysis of 40,000 randomized patients from the Chinese Acute Stroke Trial and the International Stroke Trial. Stroke 2000; 31: 1240–1249.C
  10. 10. Coull BM, Williams LS, Goldstein LB, Meschia JF, Heitzman D, Chaturvedi S, et al. Anticoagulants and antiplatelet agents in acute ischemic stroke: Report of the Joint Stroke Guideline Development Committee of the American Academy of Neurology and the American Stroke Association (a Division of the American Heart Association). Neurology 2002; 59: 13–22.C
  11. 11. Adams HP Jr. Emergent Use of anticoagulation for treatment of patients with ischemic stroke. Stroke 2002; 33: 856–861.A
  12. 12. Frey JL, Jahnke HK, Bulfinch EW. Differences in stroke between white, Hispanic, and Native American patients: The Barrow Neurological Institute Stroke Database. Stroke 1998; 29: 29–33.
  13. 13. Sacco RL, Ellenberg JH, Mohr JP, Tatemichi TK, Hier DB, Price TR, et al. Infarcts of undetermined cause: The NINCDS Stroke Data Bank. Ann Neurol 1989; 25: 382–390.
  14. 14. Erkinjuntti T, Kurz A, Gauthier S, Bullock R, Lilienfeld S, Rao C, et al. Efficacy of galanthamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: A randomized trial. Lancet 2002; 359: 1283–1290.
  15. 15. Moretti R, Torre P, Antonello RM, Cazzato G. Rivastigmine in subcortical vascular dementia: A comparison trial on efficacy and tolerability for 12 months follow-up. Eur J Neurol 2001; 8: 361–362.
  16. 16. Provinciali L, Coccia M. Poststroke and vascular depression: A critical review. Neurol Sci 2002; 22: 417–428.
  17. 17. Furlan A, Higashida R, Wechsler L, Gent M, Rowley J, Kase C, et al; The PROACT Investigators. Intra-arterial prourokinase for acute ischemic stroke: The PROACT II Study—A randomized controlled trial. JAMA 1999; 282: 2003–2011.
  18. 18. Kammersgaard LP, Rasmussen BH, Jorgensen HS, Reith J, Weber U, Olsen TS. Feasibility and safety of inducing modest hypothermia in awake patients with acute stroke through surface cooling: A case-control study. The Copenhagen Stroke Study. Stroke 2000; 31: 2251–2256.
  19. 19. The Hypothermia after Cardiac Arrest Study Group. Mild therapeutic hypothermia to improve the neurologic outcome after cardiac arrest. N Engl J Med 2002; 346: 549–556.
  20. 20. Bernard SA, Gray TW, Buist MD, Jones BM, Silvester W, Gutteridge G, et al. Treatment of comatose survivors of out-of-hospital cardiac arrest with induced hypothermia. N Engl J Med 2002; 346: 557–563.